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Abstract
Backgroud: Ovarian transplantation is a useful method for preserving the fertility of young women with cancer
who undergo radiotherapy and chemotherapy. Follicle-stimulating hormone (FSH) is use to protect transplanted
ovarian tissues from ischemia injury through promoting revascularization after transplantation, but the side effect
of high level FSH is ovarian overstimulation leading to substantial follicular loss. In this study, we investigated the
optimal usage of FSH on revascularization in the in vitro cultured ovarian tissues before and after transplantation.
Results: FSH mainly exhibited an additive response in the gene and protein expression of vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF) and follicle stimulating hormone receptor (FSHR) with
its raised concentrations (0.15 IU/ml, 0.30 IU/ml and 0.60 IU/ml) and prolonged treatment (3 h, 6 h, 12 h, 24 h). The
concentrations with 0.60 IU/ml FSH could obviously promoted the expression of VEGF, bFGF and FSHR, but under
this concentration FSH could also overstimulated the ovarian tissue leading to follicular loss. With the increase of
culture time, the gene and protein expression of VEGF and bFGF both were up-regulated in all of the FSH added
groups, but FSHR expression decreased when culture time exceeded 12 h. So we chose 0.30 IU/ml FSH added
concentration and 6 h culture time as the FSH usage condition in functional revascularization verification experiment,
and found that under this condition FSH promoted 2.5 times increase of vascular density in treated group than in
control group after ovarian tissues transplantation.
Conclusion: Ovarian intervention with 0.30 IU/ml FSH for 6 h is an optimal FSH usage condition which could accelerate
the revascularization in the allotransplanted ovarian tissue and can not produce ovarian overstimulation.
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Backgroud
Preserving fertility has been considered to be one com-
ponent of treatment in children, adolescents and women
suffering from malignant tumors and in premenopausal
patients [1–5]. Cryopreservation and transplantation of
ovarian tissue have been employed for the preservation
and restoration of women’s reproductive functions. This
approach has provided hope for those who will lose their
reproductive capacity.
More than 30 live human births have resulted from
the transplantation of cryopreserved ovarian tissue [6],
although various problems exist, such as the shortened
lifespans of the transplanted ovaries, poor response to
gonadotrophin and empty follicles without ovum [7–9],
and ischemia caused by slow post-transplantation graft
revascularization leading to substantial follicular loss. It
is very important to restore ovarian function after trans-
plantation of cryopreserved ovarian tissue, but the ap-
proaches to improve fertility restoration after this
procedure are very limited. Treatment of ovarian tissue
with vitamin E or gonadotrophins before transplantation
could reduce ischemia and improve follicular survival in
mice [10, 11]. Our previous study has shown that in vitro
intervention with human menopausal gonadotrophin
(HMG) before transplantation improved the blood supply
reconstruction and survival of the autotransplanted
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follicles, which may be associated with increased VEGF
expression[12].
Although there are a large number of studies confirming
that HMG, FSH and luteinizing hormone (LH) can pro-
mote the expression of VEGF and increase the angiogen-
esis and the vascular permeability [13, 14], the optimum
processing time and the concentration of FSH are still un-
known. It is therefore very important to investigate the
optimum therapeutic regimen of FSH in ovarian
transplantation.
The present study was designed to investigate the opti-
mal intervention by detecting the angiogenesis factor
expression and vascular generation of ovarian tissue
treated with different FSH concentrations and different
durations of in vitro cultivation. We aimed to elucidate
the therapeutic effects of FSH on cultured ovarian in
clinical application of ovarian tissue transplantation.
Methods
Animals
The experiment was approved by the Ningxia Medical
University Committee on the Use and Care of Animals.
A total of 96 females, 5-week-old, Institute of Cancer
Research (ICR) strain mice were used for this study.
They were caged in a controlled environment at 20 °C
with 12-h light/dark cycles. Standard mouse feed and
water were provided ad libitum. All mice were allowed
to acclimate to this environment for 1 week before initi-
ation of the experiment. The mice were anaesthetized
with an intraperitoneal injection of 0.3% napental
(0.1 ml/10 g bodyweight; Beshide, Wuhan, China). Be-
fore surgery, the dorsolateral skin was shaved and
antisepsis was obtained with 10% povidone iodine
solution. Next, the bilateral ovaries were removed
through small dorsolateral skin incisions, placed in Dul-
becco’s phosphate-buffered solution (DPBS) (Sijiqing,
Hangzhou, China) and were cut into two halves. Recipi-
ent mice kidneys were exposed in turn via two lateral in-
cisions in the dorsolateral skin. Two fresh or FSH
treated hemi-ovaries were immediately inserted at op-
posite poles of the two renal capsules of each recipient
by creating a subcapsular pocket between the renal cap-
sule and the renal parenchyma. After closing the
wounds, the animals were returned to the isolators
where they all made a full recovery.
Culture of ovarian tissue
The bilateral ovaries of the ICR mice in diestrus were re-
moved through small dorsolateral skin incisions placed
in DPBS and were cut into two halves (2 × 1.5 × 1 mm).
The ovarian tissues of each mouse were randomly di-
vided into five groups: control group (not cultured); FSH
0.00 culture group (FSH 0.00-CG, no FSH cultured con-
trol); FSH 0.15 culture group (FSH 0.15-CG, cultured
with FSH 0.15 IU/ml); FSH 0.30 culture group (FSH
0.30-CG, cultured with FSH 0.30 IU/ml) and FSH 0.60
culture group (FSH 0.60-CG, cultured with FSH
0.60 IU/ml). Ovarian tissue samples treated with differ-
ent doses of FSH were cultured under 20% O2 and 5%
CO2 at 37 °C for each of the culture durations (0 h, 3 h,
6 h, 12 h and 24 h).
Immunohistochemistry
Ninety-six hemi-ovaries (from 24 mice, four hemi-
ovaries from each mouse were divided with one hemi-
ovary in each FSH concentration group: FSH 0.00-CG,
FSH 0.15-CG, FSH 0.30-CG and FSH 0.60-CG) were
processed routinely in 4% paraformaldehyde for 6 h after
3 h, 6 h, 12 h and 24 h in vitro culture. In control group
(not cultured), six hemi-ovaries were removed from 6
mice without prior culture. Six ovarian tissues were used
in each experimental group for each endpoint. The
hemi-ovaries were processed routinely in 4% paraformal-
dehyde for 6 h. Paraffin sections (6 μm) were stained
with EnVision two-step immunohistochemistry (Anti-
body Diagnostica, USA) and anti-rat VEGF, bFGF and
FSHR polyclonal antibodies (1:100 dilution; Beshide,
USA). In each experimental group for each endpoint, we
used 6 hemi-ovaries. Each hemi-ovary was used to get
one section. The section we used contained the biggest
area from the cross-section of hemi-ovary. We stained
the section to quantify immunohistochemical results.
Three different high-power fields were chosen randomly,
and the VEGF, bFGF and FSHR densities were estimated
with integrated optical density. Two researchers assessed
the results of the IHC analysis and obtained the same re-
sults. Cells staining positive for each of the markers were
detected under light microscopy.
Real-time PCR
On the basis of the immunohistochemistry experiment,
we selected FSH 0.30-CG as the best treatment dose for
the follow-up experiments. Total RNA was extracted
from 60 hemi-ovaries (from 15 mice, four hemi-ovary
from each mouse was placed in each FSH concentration
group: FSH 0.00-CG and FSH 0.30-CG) using an Axy-
Prep kit (Chaoyan Biotech Co., Ltd, Shanghai, China) ac-
cording to the manufacturer’s instructions after 0 h, 3 h,
6 h, 12 h and 24 h in culture. Six ovarian tissues were
used in each experimental group for each endpoint. The
real time quantitative polymerase chain reaction (RT-
qPCR) procedure was carried out using ABI 7500fast
and ABI 7500fast Optical System Software. RT-qPCR
products were detected with SYBR Premix Ex Taq II. The
primer sequences used are as follows: β-actin: 5′-
TGGTTTTCTTGTTGCTCCCATA-3′, Rev, 5′-GGG
TGCGGAGAAGGTTCAA-3′; VEGF: Fwd, 5′-CATCTT
CAAGCCDTCCT GTGT-3′, Rev, 5′-CTCCAGGGCTTC
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Immunoblotting analysis was performed as previously
described[15]. Sixty hemi-ovaries (from 15 mice, four
hemi-ovaries from each same mouse were included in
the two different FSH concentration groups: FSH 0.00-
CG, and FSH 0.30-CG) were lysed in radioimmunopreci-
pitation assay (RIPA) buffer containing a mixture of
protease inhibitors on ice for 30 min after 0 h, 3 h, 6 h,
12 h and 24 h in culture. Six ovarian tissues were used
in each experimental group for each endpoint. The sam-
ples were then separated on 12% sodium dodecyl sulfate
(SDS) polyacrylamide gel with a 5% stacking gel under
reducing conditions and transferred to the polyvinyli-
dene difluoride (PVDF) membrane. The membranes
were blocked with 5% non-fat dry milk for 1 h and
probed with the first antibody at a concentration of
1 μg/ml for 1 h and then with a streptavidin-horseradish
peroxidase-conjugated anti-rabbit antibody (ZhongBin
GOLDENBRIDGE, China) at a dilution of 1:7000. The
resulting signal was visualized using an ECL Detection
kit (Thermo, USA) according to the manufacturer’s in-
structions. β-Actin was used as the reference. The re-
sults were analyzed using Image J Software.
2MD-FITC-Dextran perfusion of ovaries to assess
revascularization
A total of 24 hemi-ovaries (from 12 donor mice, two
hemi-ovaries from each mouse were placed in each of
the two different FSH concentration groups: FSH 0.00-
CG and FSH 0.30-CG) (six mice for each condition)
were transplanted back to 12 recipient mice under the
renal capsule after 3 h culture. For the control group, a
total of 12 hemi-ovaries (from 6 donor mice) were trans-
planted to 6 recipient mice without prior culture. At
36 h after transplantation, the mice were given 10 mg/
ml FITC conjugated Dextran with molecular weights of
2000000 daltons (2MD-FITC-Dextran) solution 0.1 ml
by intravenous injection, with the exception of 6 mice in
the control group. One hour later, the kidney with the
implant was removed, fixed in 4% paraformaldehyde,
and cut on a cryotome. In each experimental group for
each endpoint we selected 3 sections from one hemi-
ovaries. All frozen sections(40 μm) were mounted in
50% glycerin in water and viewed under a laser scanning
confocal microscope. The green fluorescent of FITC
conjugated dextran particles can be detected in renal ca-
pillaries and microvessels of the grafts after dextran per-
fusion. The area of the green fluorescent in microvessels
of the ovarian grafts and the total area of grafts were
counted by Image-Pro® Plus 6.0 (IPP 6.0) software. The
vascular density was shown as the percentage of the ovar-
ian microvessels area in the total area of ovarian grafts.
Statistical analyses
All data were expressed as the mean ± SD. VEGF, bFGF,
and the gene and protein expression of FSHR between
groups (FSH 0.00-CG, FSH 0.15-CG, FSH 0.30-CG, and
FSH 0.60-CG,) were analyzed with univariate analysis of
variance. Significance was set at P < 0.05. Multiple com-
parisons of the data were performed using the Student-
Newman-Keuls method.
Results
Expression and localization of VEGF, bFGF and FSHR in
untreated and FSH-treated ovarian tissues detected by
immunohistochemistry
The proteins of VEGF (Fig. 1), bFGF (Fig. 2) and FSHR
(Fig. 3) were mainly expressed in the cytoplasm of the
granulosa cells of the large follicle. VEGF and bFGF were
also expressed in theca cells. Interestingly, the expres-
sion levels of VEGF, bFGF and FSHR increased after
FSH treatment, and the expression of these proteins is
FSH dose dependent. The expressions of VEGF and
bFGF in the FSH 0.60-CG were significantly higher (P <
0.05) than those in FSH 0.00-CG at all of the culture
time points. The expression level of FSHR protein in
FSH 0.60-CG and 0.30-CG significantly higher (P < 0.05)
than those in FSH 0.00-CG at 3 h and 6 h, and the ex-
pression in the FSH-added group(FSH 0.60-CG and
0.30-CG) was not statistically different from FSH 0.00-
CG at 12 h and 24 h after FSH treatment. While the ex-
pressions of VEGF, bFGF and FSHR in the FSH 0.60-CG
group were no significantly different (P < 0.05) from FSH
0.30-CG at all of the culture time points. Our previous
study have shown that FSH treatment with high concen-
tration of 0.60 IU/mL could induced ovarian overstimu-
lation. Based on these experimental results and our
previous study, we selected 0.30 IU/mL FSH as the treat-
ment concentration used in follow-up experiments to
quantitatively detect VEGF, bFGF and FSHR gene and
protein temporal expression.
Gene expression of VEGF, bFGF and FSHR in FSH-treated
ovaries
Real-time quantitative PCR was carried out to further
confirm the increased expression of VEGF, bFGF and
FSHR in the FSH intervention group at different culture
times. The results of qPCR showed that the expression
level of these mRNA is time dependent. VEGF mRNA
was significantly higher (P < 0.05) at 12 h and 24 h com-
pared to the expression in FSH 0.00-CG at the same
time points (Fig. 4). The expression of VEGF mRNA was
increased 26.27 times in the FSH 0.30-CG group
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compared with that in FSH 0.00-CG after 24 h of cul-
ture. The expression of bFGF mRNA was significantly
higher (P < 0.05) in the FSH 0.30-CG at 6 h, 12 h and
24 h compared to the expression in FSH 0.00-CG at the
same time points (Fig. 4). The expression of bFGF
mRNA was increased 33.2 times in the FSH 0.30-CG
group than that in FSH 0.00-CG after 24 h of culture.
The expression of FSHR mRNA was significantly higher
(P < 0.05) at 3 h and 6 h than that in the FSH 0.00-CG
group at the same time points. The expression of FSHR
mRNA was increased 2.94 times in the FSH 0.30-CG
group than that in FSH 0.00-CG after 3 h of culture and
gradually diminished with culture time, while the ex-
pressions of VEGF, bFGF and FSHR mRNA gradually di-
minished with culture time in FSH 0.00-CG.
Protein expression of VEGF, bFGF and FSHR in FSH-treated
ovaries
The expression levels of VEGF, bFGF and FSHR were
then submitted to western blot analysis to further
evaluate their protein levels in the FSH intervention
group and the control group. The results showed that
the protein level of VEGF based on densitometry
units significantly (P < 0.05) increased during 6 h to
24 h of culture in FSH 0.30-CG compared with FSH
0.00-CG (Fig. 5). The protein level of bFGF based on
densitometry units was significantly higher (P < 0.05)
at 3 h, 6 h, 12 h and 24 h of culture compared to
the expression in the FSH 0.00-CG group. The pro-
tein level of FSHR based on densitometry units
showed a significant increase (P < 0.05) in 3 h and
Fig. 1 FSH up-regulated the protein expression of VEGF. a The immunohistochemical stainin of VEGF in four groups (FSH 0.00-CG, FSH 0.05-CG,
FSH 0.30-CG, FSH 0.60-CG) with different FSH concentration at four time points(0 h,3 h, 6 h, 12 h, 24 h) and negative control staining for 24 h
immunohistochemical endpoints. b Integrated optical density (IOD) of VEGF protein immunohistochemical stainin. Values with different superscripts in
the same time point differ significantly (P < 0.05). Bar = 50 μm
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6 h of culture in FSH 0.30-CG compared to FSH
0.00-CG. Although VEGF temporarily increased at 3 h
and 6 h of in vitro culture., the expression of VEGF,
bFGF and FSHR protein gradually diminished with
culture time in FSH 0.00-CG.
Blood perfusion in transplanted grafts
To further investigate the effect of FSH on the neo-
vascularization in the transplanted grafts, 2MD-FITC-
Dextran perfusion was used. Because VEGF and bFGF
protein expression were higher after 12 h FSH treat-
ment, and FSHR protein expression was higher after
3 h FSH treatment. While after 12 h culture FSH lead
to overstimulation of ovarian tissues, and the gene
and protein expression of FSHR were also began to
decrease after this time point. So we selected the
ovarian tissue that were cultured for 6 h with FSH to
transplant into the recipient. The green particles can
be observed in renal capillaries and microvessels of
the grafts after 2MD-FITC-Dextran perfusion. Thirty-
six hours after transplantation, the blood vessels could
be detected in all the groups, whereas no signal was
detected in the no 2MD-FITC-Dextran injected nega-
tive control group. The vascular density in FSH 0.30-
CG was significantly higher (P < 0.05) than that in
FSH 0.00-CG, while there was no significant differ-
ence between the two groups. In addition, the green
particle-filled blood vessels in FSH 0.30-CG were
more centrally located within the ovarian tissue than
those in FSH 0. 00-CG and (Fig. 6).
Fig. 2 FSH up-regulated the protein expression of bFGF. a The immunohistochemical stainin of bFGF in four groups (FSH 0.00-CG, FSH 0.05-CG,
FSH 0.30-CG, FSH 0.60-CG) with different FSH concentration at four time points(0 h,3 h, 6 h, 12 h, 24 h) and negative control staining for 24 h
immunohistochemical endpoints. b Integrated optical density (IOD) of bFGF protein protein immunohistochemical stainin. Values with different
superscripts in the same time point differ significantly (P < 0.05). Bar = 50 μm
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Discussion
Although ovarian transplantation is a very useful method
to preserve the fertility of young women who suffered
from cancer and have been treated with radiotherapy
and chemotherapy, hypoxic-ischemic damage is the
major challenge in ovarian tissue transplantation [16,
17]. Vascular remodeling is very important for ovarian
tissue survival and functional recovery after transplant-
ation. It has been noted that gonadotrophins, such as
HMG, LH and FSH, are survival factors for follicles [12,
16, 17]. It has also been reported that the administration
of FSH after the transplantation of ovarian tissue is
beneficial to the reconstruction of blood vessels in ovar-
ian tissue; however, gonadotrophin stimulation with long
time leads to loss of follicles [18–21]. The optimum
concentration and duration of FSH intervention are ex-
tremely important to promote angiogenesis. Based on
these findings, the transient intervention with the proper
dose and duration of FSH during in vitro culture of
ovarian tissue could promote the revascularization after
ovarian heterotopic transplantation.
The immunohistochemical results showed that VEGF
is mainly expressed in the cytoplasm of ovarian granu-
losa cell, theca cell and oocyte. Consisted with our re-
sults, previous studies revealed that VEGF is expressed
in oocyte of ostrich [22], rat [23], ovine [24], porcine
[25] and human [26]. In the intervention groups, with
the increase in FSH concentrations, the expression of
VEGF increased gradually. These results indicated that
VEGF expression was dose dependent. VEGF has been
Fig. 3 FSH up-regulated the protein expression of FSHR. a The immunohistochemical stainin of FSHR in four groups (FSH 0.00-CG, FSH 0.05-CG,
FSH 0.30-CG, FSH 0.60-CG) with different FSH concentration at four time points(0 h,3 h, 6 h, 12 h, 24 h) and negative control staining for 24 h
immunohistochemical endpoints. b Integrated optical density (IOD) of FSH protein immunohistochemical stainin. Values with different superscripts in
the same time point differ significantly (P < 0.05). Bar = 50 μm
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Fig. 4 FSH up-regulated the mRNA expression of VEGF, bFGF and FSHR. Real-time PCR analysis of VEGF (a), bFGF (b) and FSHR (c) in FSH 0.00-CG
and FSH 0.30-CG. The data were presented as fold changes relative to FSH 0.00-CG at 0 h. Asterisk (*) indicates a significant increase between FSH
0.00-CG and FSH 0.30-CG at the same time point (P < 0.05)
Fig. 5 FSH up-regulated the relative protein levels of VEGF, bFGF and FSHR. The relative protein expression of VEGF (a, b), bFGF (a, c) and FSHR
(a, d) in FSH 0.00-CG and FSH 0.30-CG detected by western blot. The protein levels of VEGF and bFGF based on densitometry units showed
gradual increase from 0 h to 12 h in culture in FSH 0.30-CG. The protein level of FSHR based on densitometry units showed a significant increase
from 3 h to 6 h in FSH 0.30-CG. The relative protein levels of VEGF, bFGF and FSHR decreased gradually from 6 h to 24 h in culture in FSH 0.00-CG.
Asterisk (*) indicates a significant increase between FSH 0.00-CG and FSH 0.30-CG at the same time point (P < 0.05)
Ma et al. Journal of Ovarian Research  (2017) 10:5 Page 7 of 10
regarded as a target gene of FSH [27], and the expres-
sion of VEGF is promoted by FSH [28, 29]. New evi-
dence has shown that VEGF has protective effects on
cell survival [30]. The expression of VEGF mRNA and
protein in the higher FSH concentration group (cultured
with FSH 0.30 IU/ml) was significantly higher than in
the no FSH addition group. In addition, ovaries cultured
with the highest concentration of FSH for 3 h yielded
more exudates between the host renal capsule and donor
36 h after graft transplantation and had fewer follicles
1 month after transplantation. This finding may be the
result of excessive activation of the ovaries by the higher
concentrations of FSH, causing follicular consumption
and leading to ovarian reserve loss. The longer duration of
FSH stimulation can increase the gene and protein expres-
sion of angiogenesis factors, which is helpful for the estab-
lishment of the revascularization after transplantation.
Previous studies have shown that transplanted ovaries
with an extended duration of gonadotrophin intervention
may lead to significant loss of primordial follicles [19].
Therefore, the in vitro ovarian culture time with FSH
should be appropriate.
bFGF is important for the promotion of cell mitosis.
In studies, we found bFGF promotes new blood vessel
generation and accelerates the healing of damaged tis-
sue. Ovaries of women of reproductive age with normal
ovarian function have been shown to express bFGF in
the corpus luteum, granulosa cells [31]. Ovaries of the
ostrich (struthio camelus) have been shown to express
bFGF in oocyte [22]. Sheep [32] and rat [33] oocytes also
show positive staining for bFGF. However, with aging,
ovarian function declines and bFGF expression gradually
reduces. bFGF can stimulate the rapid formation of a ca-
pillary network around a preovulatory follicle and induce
vascular change during the early corpus luteum forma-
tion. Our previous studies have confirmed that FSH up-
regulates bFGF gene expression, although little data
exists with regard to whether the amount of FSH influ-
ences the expression of bFGF. Our present results
showed that FSH can up-regulate the expression of
bFGF mRNA and protein and that the expressions are
dose dependent with the increase in FSH concentration.
This study further found that bFGF protein expression
increased with prolonged FSH culture duration. Our
studies provide a scientific basis for in vitro FSH inter-
vention to promote vascular remodeling.
In this study, we found that VEGF and bFGF gene ex-
pressions were increased with the duration of FSH cul-
ture. The amount of mRNA of VEGF and bFGF reached
their peak 24 h after ovarian culture with FSH, which
was statistically significant compared to the no-FSH
added group (P < 0.05). VEGF and bFGF protein expres-
sions were also increased with the extension of the incu-
bation time in the culture medium with FSH. The
amount VEGF and bFGF proteins reached their peaks
12 h after ovarian culture with FSH, while the ovarian
expression peak of FSHR mRNA and protein appeared
at 3 h after culture with FSH. Previous studies showed
that when endothelial cells are cultured in vitro using
medium supplemented with growth factor bFGF, the ex-
pression of VEGF was increased. If the expression of
VEGF was blocked, bFGF therefore cannot induce endo-
thelial cells to form blood vessels. Thus, endothelial cell
angiogenesis was promoted by VEGF, which was up-
regulated by bFGF [34]. The bFGF was transported to
the nucleus and enhanced VEGF transcription after
binding with its receptors. Additionally, bFGF up-
regulated the expression of VEGF, which sped up the
Fig. 6 FSH accelerate bloodstream reperfusion in transplanted ovarian tissues. A control group (not cultured): (a) number of 2MD-FITC-Dextran
granules in ovarian blood vessels 36 h after transplantation of fresh ovaries; (b) negative control (no 2MD-FITC-Dextran injected control): There
were no 2MD-FITC -Dextran granules in the ovarian tissue at 36 h after transplantation of ovaries which treated with 0.30 IU/ml FSH for 6 h; (c)
culture with 0.30 IU/ml FSH: Numerous 2MD-FITC-Dextran granules in ovarian blood vessels 36 h after transplantation of ovaries which treated with
0.30 IU/ml FSH for 6 h; (d) culture with 0.00 IU/ml FSH: Few 2MD-FITC-Dextran granules in the ovarian blood vessels 36 h after transplantation of ovaries
which treated with 0.00 IU/ml FSH for 6 h; (e). Mean vascular density of transplanted ovarian tissues. Asterisk (*) indicates a significant increase between
the two groups (P < 0.05) (×200)
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process of wound healing [35]. Therefore, bFGF and
VEGF also have synergy in the process of angiogenesis.
Ovarian tissue samples treated with different doses of
FSH were cultured under 20% O2 and 5% CO2, in which
the ovarian tissue is under the normal condition and it
is not in a hypoxia condition. Hypoxia can usually in-
duce HIF1a expression, and then up-regulate VEGF
expression which promote angiogenesis. Hence, the up-
regulated expression of VEGF was induced by FSH. Our
experimental results show that the expression of the
FSHR gene and protein reached a peak 3 h after FSH
treatment, which amplified the limited FSH effects.
In the current study, we transplanted half of the ovar-
ies that had been cultured with the concentrations of
0.30 IU/ml FSH in vitro for 6 h back to the recipient
mouse body and observed the vascularization process at
36 h after transplantation. The results demonstrated
blood perfusion from host to implanted tissue appeared
in the FSH 0.30-CG. Meanwhile, the expression of VEGF
and bFGF in the FSH 0.30-CG was significantly higher
than in the other groups. This study, in addition to pre-
vious studies, have suggested that the expression of
VEGF and bFGF were regulated by FSH during the in
vitro culture of the ovary[36–38]. The up-regulation of
VEGF and bFGF is helpful for the formation of novel
blood vessels during ovary transplantation. It also in-
creases the rate of ovary transplantation. These results
indicated that the blood perfusion between the graft and
the host was related to the addition of FSH.
Conclusion
These findings demonstrate that ovarian intervention
with 0.30 IU/ml FSH for 6 h is an optimal FSH usage
condition which could accelerate the revascularization in
the allotransplanted ovarian tissue and can not produce
ovarian overstimulation in mice.
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